Alex Baxter

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

Colin Baigent, Martin Landray, Christina Reith et al. · The Lancet · 2011 · 2.5K citations

Pharmacy, Cardiology, Pharmacotherapy +16

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

Lixin Jiang, Jemma C. Hopewell, Jing Li et al. · European Heart Journal · 2013 · 673 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +8

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease

Colin Baigent, Martin Landray, Craig Leaper et al. · American Journal of Kidney Diseases · 2005 · 209 citations

Medicine, Cardiology, Pharmacology +10

Effects of Lowering LDL Cholesterol on Progression of Kidney Disease

Richard Haynes, David Lewis, Jonathan Emberson et al. · Journal of the American Society of Nephrology · 2014 · 177 citations · Full text

Medicine, Nephrology, Pharmacotherapy +16

The Second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: A Randomized Controlled Study of the Biochemical Safety and Efficacy of Adding Ezetimibe to Simvastatin as Initial Therapy Among Patients With CKD

Martin Landray, Colin Baigent, Craig Leaper et al. · American Journal of Kidney Diseases · 2006 · 108 citations

Medicine, Pharmacology, Pharmacotherapy +11